A metformin kidney damage lawsuit is difficult to win on the theory that the drug itself injured your kidneys. Current medical evidence does not establish metformin as a cause of kidney damage, and the drug’s label already carries FDA-required warnings, including a boxed warning about lactic acidosis and specific kidney-function thresholds for prescribing. The active metformin litigation most people encounter online is different: it centers on NDMA contamination discovered in certain extended-release formulations in 2020, and those claims focus on a carcinogenic impurity rather than kidney injury. Which harm you actually experienced determines whether you have a viable case, whom you can name, and what legal theory has any chance of surviving.
Why a Kidney-Damage Theory Is Hard to Win
The relationship between metformin and kidneys is not “metformin damages kidneys.” Type 2 diabetes itself is one of the leading causes of chronic kidney disease, so any decline in kidney function during metformin treatment has an obvious alternative explanation that a defendant will press hard.
A systematic review looking at whether metformin affects kidney disease progression found that, compared to placebo, metformin may actually produce a slightly smaller decline in kidney function, though the researchers rated the evidence low certainty and said there was not enough data to support or refute using metformin to protect kidneys. Serious adverse events, including lactic acidosis, were rare across the studies.1NCBI. Metformin for Preventing the Progression of Chronic Kidney Disease
The FDA has addressed metformin’s interaction with kidney function directly. A 2016 safety communication set specific eGFR thresholds: doctors should not start metformin when a patient’s estimated glomerular filtration rate falls between 30 and 45, and must stop it if eGFR drops below 30.2U.S. Food and Drug Administration. Drug Safety Communication – FDA Revises Warnings Regarding Use of Metformin in Certain Patients With Reduced Kidney Function The drug also carries a boxed warning about lactic acidosis that lists renal impairment as a primary risk factor.3U.S. Food and Drug Administration. KAZANO (Alogliptin and Metformin Hydrochloride) Full Prescribing Information
Those warnings are the biggest obstacle to a failure-to-warn claim. If the label already discloses the kidney-related risk, arguing that the manufacturer failed to warn about that risk becomes very difficult. One FAERS-based study noted that after the FDA expanded metformin’s approval in 2016 to patients with mild-to-moderate kidney impairment, reports of lactic acidosis in patients with renal problems increased.4American Diabetes Association. Metformin-Cimetidine Drug Interaction and Risk of Lactic Acidosis in Renal Failure The mechanism in most of those cases was that patients with declining kidney function accumulated dangerous levels of the drug, not that the drug attacked healthy kidneys. That is the argument the label already anticipates.
The NDMA Contamination Lawsuits Are Different
If you have been reading about metformin lawsuits, most of what you are finding relates to a 2020 problem that has nothing to do with kidney damage as a legal theory. The FDA discovered that certain extended-release metformin formulations contained N-Nitrosodimethylamine (NDMA), a probable human carcinogen, above the acceptable daily intake limit of 96 nanograms per day.5U.S. Food and Drug Administration. CDER Nitrosamine Impurity Acceptable Intake Limits The contamination affected only extended-release versions. Immediate-release metformin and the active ingredient itself tested clean.6U.S. Food and Drug Administration. Questions and Answers – NDMA Impurities in Metformin Products
The FDA recommended recalls from five manufacturers of extended-release metformin and directed all ER manufacturers to test at-risk products before releasing each batch.6U.S. Food and Drug Administration. Questions and Answers – NDMA Impurities in Metformin Products Amneal Pharmaceuticals was among the companies whose products appeared on the recall list.7U.S. Food and Drug Administration. Search List of Recalled Metformin Products
The resulting claims were consolidated into a multidistrict proceeding, In re Metformin Marketing and Sales Practices Litigation, Case No. 20-2324, in the U.S. District Court for the District of New Jersey.8GovInfo. IN RE METFORMIN MARKETING AND SALES PRACTICES LITIGATION Those consolidated claims focus on economic loss from contaminated product rather than kidney damage. The legal theory usually fits under manufacturing defect: the product as delivered did not match its approved specifications because it contained a carcinogenic impurity above acceptable limits. You do not need to prove the drug is inherently dangerous, only that specific lots deviated from what the FDA approved.
If you took extended-release metformin from a recalled manufacturer during the affected period, this MDL is a more realistic path than a standalone kidney-injury claim.
The Generic Drug Preemption Barrier
Before you file anything, check whether the metformin you took was generic. The vast majority of metformin dispensed in the United States is, and two Supreme Court decisions have sharply limited what you can sue a generic manufacturer for.
In PLIVA, Inc. v. Mensing (2011), the Court held that federal law preempts state failure-to-warn claims against generic drug manufacturers. Federal regulations require generic drugs to carry the same labeling as their brand-name counterparts, which makes it impossible for a generic manufacturer to independently strengthen its warnings.9Justia U.S. Supreme Court. PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011) Two years later, Mutual Pharmaceutical Co. v. Bartlett (2013) extended preemption to state-law design defect claims against generic manufacturers, on the same logic: the manufacturer cannot comply with both a federal duty to keep the label and composition unchanged and a state-law duty to alter them.10Justia U.S. Supreme Court. Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472 (2013)
The practical result: if your metformin was generic, failure-to-warn and design-defect claims against the manufacturer are severely restricted in most circumstances. Manufacturing defect claims can survive preemption because the argument is not that the label or design should have been different, but that the specific product deviated from its approved specifications. That is why NDMA contamination claims move forward where a general kidney-injury theory stalls. Brand-name metformin makes up a small share of prescriptions, so most people asking this question are looking at a generic case with those preemption walls in place.
Proving That Metformin, Not Diabetes, Caused the Injury
Causation is the heart of any pharmaceutical injury claim and usually the hardest element to establish. You need to show metformin was a proximate cause of your injury, meaning a foreseeable and substantial factor in producing it rather than a remote contributor.
For a kidney claim, that means ruling out diabetes itself. Diabetes is one of the top causes of kidney disease, and separating its effects from those of a medication used to treat it takes detailed medical records, lab work tracking your kidney function over time, and typically testimony from a nephrologist or pharmacologist who can walk a jury through the timeline. If your kidney function was already declining when you started metformin, or if your diabetes was poorly controlled, a defendant will argue the disease caused the damage. Those arguments often win.
Defenses You Should Expect
Manufacturers in metformin cases draw from a well-worn playbook.
The first defense is the causation attack described above: your kidney problems trace to diabetes, high blood pressure, aging, or other medications. Because most metformin users have diabetes and diabetes frequently damages kidneys, this defense is often dispositive.
The second is the learned intermediary doctrine. In most states, pharmaceutical manufacturers satisfy their duty to warn by giving risk information to the prescribing physician rather than the patient. If the manufacturer adequately warned your doctor, it may avoid liability even if you never personally saw the warning.
The third is federal preemption for generic manufacturers, discussed above.9Justia U.S. Supreme Court. PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011)
The fourth is label compliance. Manufacturers point to the boxed warning on lactic acidosis and the eGFR-based contraindications and argue the label already communicated every known risk. For kidney-related claims specifically, this defense has teeth.
How Long You Have to File
Every state sets its own statute of limitations for product liability claims, and missing the deadline bars your case regardless of its merits. Most states allow between one and four years, with two years being the most common window.
When the clock starts is often the harder question. Many states follow the discovery rule, which begins the limitations period not when the injury occurs but when you discover or reasonably should have discovered it. If your kidney function declined gradually across years of metformin use, the question becomes when you knew or should have known metformin might be the cause. Courts will not extend the deadline indefinitely because you did not investigate symptoms when they first appeared.
Some states also have a statute of repose, an outer deadline that runs regardless of discovery. Where one applies to product liability, it typically runs 10 to 12 years from the date you purchased the product. Once that period ends, the discovery rule cannot save the claim.
What You Could Recover
If you can establish liability and causation, damages in a pharmaceutical injury case usually fall into these categories:
- Medical expenses, including hospital stays, specialist visits, lab work, prescriptions, and dialysis.
- Future medical costs, projected forward and typically reduced to present value.
- Lost wages from time missed during treatment and recovery.
- Lost earning capacity, if a permanent kidney condition reduces your long-term ability to work.
- Pain and suffering, which varies widely by jurisdiction and is harder to quantify.
Punitive damages are theoretically available but require proof that the manufacturer acted with willful disregard for patient safety rather than mere negligence. Courts set a high bar, and it rarely applies when a manufacturer was following FDA-approved labeling.
What It Costs to Pursue a Claim
Most pharmaceutical injury attorneys work on contingency, so you pay no upfront legal fees. The attorney takes a percentage of any recovery, typically around 33%, and sometimes up to 40% if the case goes to trial. Some states cap contingency percentages by statute. If you lose, you generally owe no attorney fees, though you may still be responsible for out-of-pocket costs such as filing fees and expert charges.
Expert witnesses drive the biggest costs. Medical experts commonly charge $300 to $600 per hour, and specialists can charge considerably more. A metformin kidney case might require a nephrologist, a pharmacologist, and possibly a toxicologist, each billing separately for records review, deposition, and trial testimony. Your attorney typically fronts these costs and recoups them from the recovery, which reduces your net compensation.
What to Do Now
Be honest with yourself about which case you actually have. A claim built on the idea that metformin injured your kidneys must clear medical causation independent of your diabetes, survive preemption if the drug was generic, and overcome the existing boxed warning and eGFR guidelines. Few claims clear all three. A claim built on NDMA-contaminated extended-release metformin from a recalled manufacturer stands on much firmer ground, with a documented contamination event, public recalls, and an existing MDL to plug into.
Either way, preserve your records now. Pharmacy records showing the specific manufacturer, formulation, and lot numbers you took; lab results tracking your kidney function over time; and notes from your prescribing physician about why metformin was chosen are the evidence any attorney will ask for first. Gather them before any filing deadline gets closer.